Search company, investor...
Pilloxa company logo


Founded Year



Acquired | Acquired

Total Raised




About Pilloxa

Pilloxa offers a platform to engage patients and develops a medical box that connects to the mobile phone and alerts users or relatives to take their medicine. The company was founded in 2015 and is based in Stockholm, Sweden. In August 2022, Pilloxa was acquired by iZafe.87M.

Headquarters Location

Sankt Eriksgatan 48E

Stockholm, 112 34,


+46 70 - 245 29 09

Missing: Pilloxa's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Pilloxa's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Pilloxa

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Pilloxa is included in 1 Expert Collection, including Digital Health.


Digital Health

10,338 items

The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.

Latest Pilloxa News

iZafe Signs a Letter of Intent to Acquire Pilloxa AB

Aug 18, 2022

August 18, 2022 GMT STOCKHOLM, SE / ACCESSWIRE / August 18, 2022 / iZafe Group (STO:IZAFE-B) iZafe Group AB (publ) (“iZafe” or the “Company”) has signed a Letter of Intent with Pilloxa AB (“Pilloxa”) regarding the acquisition of 100 percent of the shares in Pilloxa (the “Acquisition”). Pilloxa has developed a technical platform for better compliance that pharmaceutical companies use to design digital patient support. A new company within digital health is created through the acquisition that is well positioned to become a leading company within better and more secure use of pharmaceuticals. The Letter of Intent concerns 100 percent of the shares in Pilloxa. The purchase price is paid at 100 percent of 70,874,308 newly issued iZafe shares at an indicative value of approximately SEK 30 million. The indicative value of Pilloxa may be adjusted upwards or downwards depending on the development of the share price on the day of entry. Given that the indicative offer is accepted, the shareholders in Pilloxa will own 50 percent of the shares in the joint company after the takeover, which is expected to take place during Q3 2022. The acquisition is subject to approval at an extraordinary general meeting of iZafe Group AB. More information about the extraordinary general meeting will be published in a separate press release. ADVERTISEMENT - For a long time, we have developed the drug dispensing robot Dosell and established a network of partners and collaborations that see great value in medication data to enable proactive care. Through the acquisition of Pilloxa, we are now taking the next step towards our vision of improved health with better compliance, whose digital platform can be leveraged and integrated directly into our existing products and offerings. It creates an attractive and complete offer, access to a larger customer base and additional sales channels. Together we are creating something unique within the framework of digital health, says Anders Segerström, CEO of iZafe. - With Pilloxa’s digital offering and long-term collaboration with the pharmaceutical industry and together with iZafe, we are able to offer a comprehensive solution for our customers; patients, healthcare professionals and the pharmaceutical industry. Pilloxa’s promise to our customers today is a complete digital solution for patient support within one month of the initiation meeting. We are therefore used to rapid integrations and will immediately begin to work on offering a joint digital solution, says Helena Rönnqvist, CEO of Pilloxa. ADVERTISEMENT Incorrect or inadequate medication is a major and expensive problem for both the individual and drug development companies and costs society significant sums. Offering patients support to take their medication correctly has been shown to be an effective way to achieve better medical outcomes. Both iZafe and Pilloxa today offer solutions that support patients in safe medical treatment. The merger means a broader and attractive offer to both healthcare providers, the pharmaceutical industry and consumers, broadens the customer base and is expected to contribute to accelerated market penetration through clear sales and margin synergies. ADVERTISEMENT About Pilloxa Pilloxa is a Swedish company that develops apps for patients to support them in adherence to their treatment and to connect patients, healthcare providers and the pharmaceutical industry. The company provides a SaaS platform where pharmaceutical companies and other customers can design digital patient support quickly, securely and at a low cost. Connected aids such as Pilloxa’s self-developed smart medication dose can also be connected to the service to support patients in taking the correct medication. Customers and partners of Pilloxa include pharmaceutical companies such as Bayer Nordics and the Nordic office of Chiesi Global Rare Diseases, university hospitals such as the University Hospital in Oslo and universities such as the University of Gothenburg. Advisor About Us iZafe Group is a Swedish Life-Science company that develops and markets medical and digital security solutions to create safer drug handling at home. The company’s digital medication dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. The products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life. Customers today consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe Group sells primarily through well-established partners who already have long and deep customer relationships with the priority customer groups. The head office is located in Stockholm. ADVERTISEMENT The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company’s Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: . Further information is available at . This information is information that iZafe Group is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2022-08-18 08:30 CEST. Attachments

Pilloxa Frequently Asked Questions (FAQ)

  • When was Pilloxa founded?

    Pilloxa was founded in 2015.

  • Where is Pilloxa's headquarters?

    Pilloxa's headquarters is located at Sankt Eriksgatan 48E, Stockholm.

  • What is Pilloxa's latest funding round?

    Pilloxa's latest funding round is Acquired.

  • How much did Pilloxa raise?

    Pilloxa raised a total of $2.59M.

  • Who are the investors of Pilloxa?

    Investors of Pilloxa include iZafe, KI Innovations, The Swedish Agency for Economic and Regional Growth, Karolinska Institutet, Fredrik Lind and 10 more.

  • Who are Pilloxa's competitors?

    Competitors of Pilloxa include Popit.

Compare Pilloxa to Competitors

MediSafe Logo

MediSafe develops a medication engagement platform. The platform helps people integrate healthier behavior into their daily lives with a cloud-synced mobile medication management system. It offers solutions, data insights, research, webinars, case studies, and more. The company is founded in 2012 and is based in Needham, Massachusetts.

Mevia Logo

Mevia develops intelligent solutions for the healthcare industry, helping patients take their medications at the right time via its intelligent pillbox and complimentary app. The company aims to connect patients, healthcare, and relatives to allow all to benefit from personalized healthcare.

etectRx Logo

etectRx developed an ID-Capsule system to help clinicians and researchers track patient ingestion events.

Perx Health Logo
Perx Health

Perx develops a user-first smartphone application to motivate people to take medication as prescribed. The company's application reminds, educates, and monitors the user's medication regime and also gives users the opportunity to earn rewards every time they stick to the schedule. It was founded in 2016 and is based in Sydney, Australia.

Popit Logo

Popit is a system to ensure people take pills at the proper time. It uses pill detection technology to automatically keep track of pills. The company was founded in 2015 and is based in Espoo, Finland.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.